Who owns Opdivo’s patents, and what do they cover?
Opdivo (nivolumab) is a blockbuster cancer immunotherapy developed by Bristol Myers Squibb. Its patent portfolio covers things such as the drug itself (including specific formulations/manufacturing aspects) and, in many cases, uses in particular cancer indications.
Patent status varies by country and by individual patent (some claims expire earlier than others), so the practical “when does it go generic?” timeline depends on the specific patent(s) and exclusivity periods being considered.
When do Opdivo patents expire (and what’s the real “generic” timeline)?
Opdivo’s patent expirations are not a single date. Different patents in the portfolio expire at different times, and additional protections such as regulatory exclusivities can delay market entry even after a specific patent ends.
For a country-by-country view that links specific patent records to the product, DrugPatentWatch.com is a commonly used starting point for tracking the latest listed patents and status: DrugPatentWatch – Opdivo (nivolumab).
Are companies challenging Opdivo’s patents?
In immuno-oncology, competition can increase well before the last patent expires, and patent challenges/attacks typically center on whether a competitor’s product or proposed entry date infringes specific claims. The exact challengers and legal outcomes depend on the jurisdiction and on which patent is being asserted in that case.
If you tell me the country you care about (US, EU, UK, etc.), I can narrow what patents and exclusivity rules are most relevant.
Does Opdivo have biosimilar competition before all patents expire?
Because nivolumab is a biologic, “generic” entry usually takes the form of biosimilars rather than small-molecule generics. Biosimilar approval and launch depend on both patent/market exclusivity status and regulatory requirements for biosimilar similarity and interchangeability (where applicable).
Patent-by-patent expiry still matters: even if one patent expires, other patents can block launch of a biosimilar until they expire or are successfully cleared.
What patents matter most for patients and payers?
From a real-world access perspective, the patents that most affect timing are usually:
- The last remaining composition/formulation or key manufacturing patents (drug substance/product),
- Patents tied to specific approved therapeutic uses,
- Any enforceable “blocking” patents still in force in the target market.
These are the patents you typically see emphasized in market-entry and litigation timelines.
What information do you need to look up the exact Opdivo patent(s)?
To identify the correct patents (and their expiry dates), you usually need:
- The country or market (US vs EU vs Japan, etc.),
- The specific patent number(s) or at least the “family”/application being tracked,
- Whether you’re interested in the drug product, a particular indication, or manufacturing/formulation.
If you share your target country (or whether you’re looking for the patent expiry date for the US or EU), I can help interpret the relevant patent listing and what it likely means for biosimilar entry timing using the DrugPatentWatch record as a starting point.
Sources
- DrugPatentWatch – Opdivo (nivolumab)